Abstract:Introduction: The drug discovery and development domain has witnessed remarkable advancements due to the integration of computational methods, particularly Computer-Aided Drug Design (CADD). Discovering and creating new drugs involves structural modifications to enhance their effectiveness and physical attributes. This frequently includes employing semisynthetic techniques to investigate structure-activity relationships thoroughly. Noticeable progress in molecular biology, computational chemistry, combinatorial chemistry, and highthroughput screening is steering transformative changes in the pharmaceutical industry. Background: High blood pressure or hypertension, a significant health issue, elevates the chances of heart, kidney, and brain complications, among other health concerns. It's a leading cause of untimely mortality globally. Therefore, it is important to search for new antihypertensive compounds that have fewer side effects and higher therapeutic activity. Methods: Following molecular docking of the pyridazine derivatives, compounds were subjected to In-silico ADMET analysis. Subsequently, a low molecular weight compound was synthesized. Among the synthesized compounds characterization procedures include TLC, FT-IR, 1HNMR, and LC-MS techniques. Result: Compound 8 exhibited the most favorable molecular docking results with alpha A1 and beta 1 adrenergic receptors. Compounds 3, 5, and 6 fulfilled the essential ADMET criteria. Subsequently, Compounds 3, 4, and 5 underwent additional synthesis and characterization procedures, including TLC, FT-IR, 1H-NMR, and LC-MS techniques. Conclusion: Similar behavior was observed in compounds 6, 8, 10, and 11, all violating Pfizer's 3/75 rules in terms of TPAS. Hydrazinolysis of these b-benzoyl propionic acids produced pyridazine, which was utilized in synthesizing pyridazine derivatives. TLC, FT-IR, 1HNMR, and LCMS have characterized the compounds.

Synthesis of 1-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)-2-formyl Piperazine

Asymmetric Synthesis of N-protected 3-Methylpiperidin-2-one and Its Diastereoisomer

A Novel Asymmetric Synthesis of Cis-(3r, 4R)-N-(tert-butoxycarbonyl)-4-methyl-3-(methylamino) Piperidine

Synthesis of Tert-Butyl-4-methyl-3-oxopiperidine-1-carboxylate

The Preparation of 8-[4-[4-(2-pyrimidinyl)-1-piperaziny]butyl]-8-azaspiro[4,5] Decane-7,9-dione Hydrochloride

Synthesis, Crystal Structures and Xanthine Oxidase Inhibitory Activity of 2-(Benzylthio)-5-[1-(4-Fluorobenzyl)-3-Phenyl-1H-Pyrazol-5-Yl]-1,3,4-Oxadiazoles Derivatives

Convenient Synthesis and Characterization of Novel 4-[2-ethoxy-5-(4-methyl-1-piperazinesulphonyl)benzamido]-3-isobutyl-1-methyl-1h-pyrazole-5-carboxamide: Key Precursor for Isobutyl Sildenafil

Study on Synthesis of Donepezil

Novel and Efficient Method to Synthesize N‐Benzyl‐4‐formyl‐piperidine.

Design, Syntheses, and Characterization of Piperazine Based Chemokine Receptor CCR5 Antagonists As Anti Prostate Cancer Agents.

Pyridazine Derivatives: Molecular Docking, ADMET Prediction, and Synthesis for Antihypertensive Activity

One-Pot Synthesis of 2-Trifluoromethyl and 2-Difluoromethyl Substituted Benzo-1,3-diazoles.

An improved route to urapidil from 1-(2-methoxyphenyl)piperazine and oxetane

Synthesis and spectroscopic investigation of substituted piperazine-2,5-dione derivatives

Mild and Efficient Synthesis of Para-Substituted 2-Hydroxymethyl Piperazine

Synthesis, In Vivo, ADME Determination, and Molecular Docking Studies of 1,3,4‐Oxadiazoles Containing Pyridine and Piperazine Moieties as New Diuretic Agents

Design, synthesis and biological evaluation of 2,4-disubstituted oxazole derivatives as potential PDE4 inhibitors

Synthesis and pharmacological activities of 1,1-dialkyl-4 (3-bromopropionyl) piperazinium bromides

Synthesis and Bioactivity of 3,5-Dimethylpyrazole Derivatives As Potential PDE4 Inhibitors.

Novel Piperazine Derivatives as Potent Antihistamine, Anti-Inflammatory, and Anticancer Agents, their Synthesis and Characterization